Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: A prospective observational study
Journal
Vaccine
Journal Volume
22
Journal Issue
15-16
Pages
2006-2012
Date Issued
2004
Author(s)
Abstract
To assess the impact of vaccination with 23-valent pneumococcal polysaccharide vaccine on the risks for development of pneumococcal disease, all-cause community-acquired pneumonia, HIV progression, and mortality and immunologic and virologic responses among HIV-1-infected patients treated with highly active antiretroviral therapy (HAART), we conducted a 2-year prospective observational cohort study at a university hospital in Taiwan. A total of 305 HIV-1-infected patients who received 23-valent pneumococcal vaccine (vaccinees) and 203 patients who did not (non-vaccinees) were prospectively observed between 1 June 2000 and 31 October 2002. Changes of CD4+ and plasma viral load (PVL) from baseline to week 4 of vaccination were assessed in 31 randomly selected vaccinees. The incidence of pneumococcal disease and bacteremia of vaccinees was 2.1 per 1000 patient-years (PY) (95% confidence interval (95% CI), 1.7-2.5 per 1000 PY) over the median observation of 641 days (range, 37-832 days) following vaccination while that of non-vaccinee was 21.8 per 1000 PY (95% CI, 20.1-23.7 per 1000 PY) and 7.3 per 1000 PY (95% CI, 7.0-7.6 per 1000 PY), respectively, over the observation of 500 days (range, 32-851 days), with an adjusted odds ratio (AOR) for developing pneumococcal disease of 0.085 (95% CI, 0.010-0.735) and for bacteremia of 0.22 (95% CI, 0.018-2.561). The median CD4+ count increased by 45×106 l-1 (P=0.01) and median PVL change was 0 log10 copies/ml (range of decrease, -0.74 to 2.47 log10 copies/ml) after 1 month of pneumococcal vaccination among the subgroup of 31 vaccinees receiving HAART. The median CD4+ count increase from baseline to the end of study was 149×106 l-1 for vaccinees and 107×106 l-1 for non-vaccinees (P=0.21). The AOR of developing all-cause community-acquired pneumonia and new AIDS-defining opportunistic illnesses (OI) of vaccinees as compared to non-vaccinees was 1.876 (95% CI, 0.785-4.485) and 0.567 (95% CI, 0.217-1.484), respectively. Death rate of vaccinees and non-vaccinees was 17.7 per 1000 PY (95% CI, 16.5-18.9 per 1000 PY) and 80.5 per 1000 PY (95% CI, 77.1-83.9 per 1000 PY), respectively. Adjusted hazard ratio for death of vaccinees as compared with non-vaccinees was 0.733 (95% CI, 0.236-2.274). Our data suggested that vaccination with 23-valent pneumococcal polysaccharide vaccine and receipt of HAART were associated with reduced risks for pneumococcal disease among HIV-1-infected patients receiving HAART. Vaccination did not increase the risks of all-cause community-acquired pneumonia, HIV progression, and mortality. Vaccination did not increase PVL or decrease CD4+ among HIV-1-infected patients receiving HAART. ? 2003 Elsevier Ltd. All rights reserved.
SDGs
Other Subjects
antiretrovirus agent; cotrimoxazole; macrolide; Pneumococcus vaccine; polysaccharide; rifamycin; adult; aged; article; bacteremia; cell count; clinical trial; community acquired pneumonia; confidence interval; female; hazard; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; incidence; major clinical study; male; mortality; priority journal; risk; Streptococcus infection; T lymphocyte; Taiwan; vaccination; virus load; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Disease Progression; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pneumococcal Infections; Pneumococcal Vaccines; Polysaccharides; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Viral Load
Type
journal article